sulumimab

Sulumimab is an investigational monoclonal antibody described in clinical trial contexts (e.g., ChiCTR2600123343) as a conversion therapy for advanced gastric adenocarcinoma and gastroesophageal junction (GEJ) adenocarcinoma. It is evaluated in combination with the CAPOX chemotherapy regimen, immunonutrition, and probiotics to facilitate R0 resection in patients with severe lymph node metastasis or oligometastatic disease. Based on the trial design and therapeutic area, sulumimab likely functions as an immune checkpoint inhibitor targeting the programmed cell death protein 1 (PD-1) pathway. However, the name sulumimab is not found in official drug registries or international nonproprietary name (INN) lists, and the provided trial details correspond to studies involving serplulimab, suggesting this may be a variant spelling or synthetic identifier.

Other names

sulumimab